☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Fenebrutinib
Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)
September 9, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.